We welcome our next speaker in our series, Dr. Kristy Richards. She is an Associate Professor with the Department of Biomedical Sciences, in the College of Veterinary Medicine at Cornell University, as well as the Department of Medicine at Weill Cornell Medical College. Her research is on translational lymphoma with a focus on comparative oncology.
Her talk is entitled "Cross-campus collaboration for experimental therapeutic development: PAThways to success".
Abstract: Therapeutic development costs are rising exponentially, with the average cost of each new FDA approved agent now estimated at $2.6 billion. In the era of precision medicine, with the need for many new agents and combinations of agents, this is obviously not a sustainable path to success. More accurate preclinical development is needed, as most new therapeutics fail during clinical trial testing. To that end, we have developed the Progressive Assessment of Therapeutics (PATh) program, which is designed to optimize each aspect of preclinical testing. Better in vitro modeling with 3-D organoid culture, better mouse genetic engineering with CRISPR/Cas9, patient derived xenograft cultures, and canine models all combine to form a more robust preclinical development platform. Utilizing cross-campus collaborations, we aim to accelerate therapeutic development while making it more accurate at the same time. Examples of PATh’s application to development of new lymphoma therapeutics in development will be discussed.
Dr. Kristy Richards
Cornell University & Weill Cornell Medical College
No recent activity